News

We send the latest information from SMC Laboratories.

2020.12.02

NEWS RELEASE

CytoDyn announces first patient enrolled in Phase 2 study for NASH

CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 …

READ MORE

2020.10.21

NEWS RELEASE

Inventiva announces FDA has granted Breakthrough Therapy designation to lanifibranor in NASH

Inventiva (France) announced on 12 October, 2020, FDA haas granted Breakthrough Therapy designation to lanifib…

READ MORE

2020.10.13

NEWS RELEASE

Our clients’ presentations at AASLD ~The Liver Meeting Digital Experience~

Our clients presented data on treatment of NASH using STAMTM model at the AASLD ~The Liver Meeting Digital Exp…

READ MORE

2020.10.07

NEWS RELEASE

Virginia Comonwealth University's publication in Journal of lipid research

SMC announces that Virginia Commonwealth University (Virginia) has published the results of a study using STAM…

READ MORE

2020.09.30

PUBLICATION

University of Yamanashi's publication in Clinical and Experimental Gastroenterology

SMC announces that University of Yamanashi (Japan) has published the results of a study using STAMTM mouse mod…

READ MORE

2020.09.23

NEWS RELEASE

Aldafermin improves fibrosis in patiants with NASH

NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its p…

READ MORE

2020.09.16

NEWS RELEASE

89bio announces positive topline results from its phase 1b/2a trial of BIO89-100 in NASH

89bio (Israel) announced on 14 September, 2020, positive topline results from its Phase 1b/2a trial with BIO89…

READ MORE

2020.09.08

NEWS RELEASE

Gilead Sciences, Inc. presented results of the phase 2b ATLAS trial at EASL ~The Digital International Liver Congress™ 2020 ~

Gilead Sciences, Inc. (USA) presented on August, 2020, the results of the phase 2b trial for NASH cirrhosis at…

READ MORE

2020.09.01

EVENT

Our clients’ presentations at EASL ~The Digital International Liver Congress™ 2020 ~

Our clients presented data on treatment of NASH using STAMTM model at the EASL ~The Digital International Live…

READ MORE

2020.08.25

NEWS RELEASE

Galectin Therapeutics announces commencement of patient enrolment of the adaptively-designed Phase 2b/3 trial of Belapectin (GR-MD-02) in NASH cirrhosis

Galectin Therapeutics (USA) announced on June 30, 2020, the commencement of patient enrolment of the adaptivel…

READ MORE

Page 16 of 20First1415161718Last